Archit Organosys Limited Overview
Archit Organosys Limited is a Gujarat-based, promoter-controlled micro-cap producer of chloroacetyl chemistry — principally monochloroacetic acid (MCA), sodium monochloroacetate (SMCA), chloroacetyl chloride (CAC) and trichloroacetyl chloride (TCAC) — supplying intermediates into agrochemicals (notably 2,4-D herbicide), pharmaceuticals (ibuprofen, diclofenac, aceclofenac), oilfield carboxymethyl cellulose, surfactants, cosmetics and pigments. It operates two manufacturing sites (Naroda GIDC, Ahmedabad and Narmad, Bhavnagar) and supplements manufacturing with trading of solvents and organic intermediates. With FY2026 revenue of INR 1,410 M (≈USD 16–17 M) and net income of INR 80.3 M, it is a sub-scale niche player in a global MCA industry dominated by Nouryon and CABB, and in India by the Nouryon–Atul joint venture Anaven. Its investment case rests on cyclical margin recovery, a debt-reduction track record, and a pending — recently withdrawn and to-be-restructured — related-party acquisition of Archit Life Science Limited that could transform its scale and capital structure.
What the company does
Archit Organosys manufactures and trades chemicals. Its core manufactured portfolio is built around the chlorination of acetic acid: chlorine reacts with acetic acid (with acetic anhydride as a catalyst source) to yield MCA, which is then either sold as acid, neutralised to SMCA, or carried further into acid chlorides such as CAC and TCAC. S&P's profile describes the company as providing MCA and SMCA for synthesis of agricultural chemicals, cosmetic surfactants, oil-drilling chemicals and plastic additives, plus organic chemicals, pigments and specialty derivatives, and adhesives and sealants sold under the "AOL" brand.
Company-sourced descriptions (relayed through IIFL, Kotak and MarketScreener summaries) state that major customers include large Indian and international companies in agrochemicals, pharmaceuticals and cosmetics, and that the company sells across India as well as to the USA, Europe, Latin America, other Asian countries and South Africa.
Company's own reporting description
In its BSE results filings and annual reports the company identifies a single operating segment — "Manufacturing and Trading of Chemicals and Organics" — with two geographic segments, India and Rest of the World (MarketScreener; TradingView; S&P/SA geographic data). Screener's "About" text, drawn from the FY2023 annual report, characterises the company as engaged in manufacturing and trading of chemicals and organics.
Revenue model
| Revenue stream | Nature | Disclosure status |
|---|---|---|
| Manufactured goods (MCA, SMCA, CAC, TCAC, pigments, sealants) | Product sales, spot and contract, B2B | Split vs. trading not publicly disclosed in reviewed sources (Screener lists "Manufacturing share of revenue", "MCA share" and "CAC share" as extracted metrics behind a paywall) |
| Traded goods (ethyl acetate, acetic anhydride, toluene and other organics/specialty chemicals) | Merchanting margin | ICRA (2017) confirms trading of these products; ScanX notes a sharp FY2026 shift from raw-material consumption toward purchases of stock-in-trade, implying a rising trading share |
| Other operating revenue (export incentives, scrap) | Ancillary | S&P/SA "revenue as reported" (INR 1,438 M FY2026) exceeds operating revenue (INR 1,410 M) by other items |
There is no subscription, licensing or service revenue. The model is a pure industrial B2B product/trading model.
Value-chain position
Archit sits in the mid-stream intermediates layer: it buys commodity feedstocks (acetic acid — which industry studies estimate at roughly 60–70% of MCA operating cost — chlorine, acetic anhydride, caustic soda) and sells functional intermediates to formulators and active-ingredient manufacturers. It is not backward-integrated into chlor-alkali (unlike the Atul–Nouryon Anaven JV, which uses Atul's own chlorine and hydrogen), which structurally exposes its margins to purchased-chlorine and acetic-acid pricing. It is also not forward-integrated into the agro-active or pharma API layers.
Customer types and end-markets
| End-market | Archit products used | Example downstream products |
|---|---|---|
| Agrochemicals | MCA, CAC | 2,4-D acid herbicide, other phenoxy herbicides, glyphosate-route intermediates |
| Pharmaceuticals | MCA, CAC | Ibuprofen, diclofenac, aceclofenac intermediates |
| Oilfield chemicals | SMCA/MCA | Carboxymethyl cellulose (CMC) for drilling fluids |
| Surfactants & personal care | MCA/SMCA | Betaine-type surfactants, cosmetics, daily personal-use products |
| Pigments | MCA derivatives | Organic pigments |
| Plastic additives | MCA derivatives | Additives |
| Construction/DIY | AOL adhesives & sealants | Sealant range |
(Sources: IIFL/Kotak summaries; S&P profile; Screener key points.)
Independent characterisation
Archit is best understood as a sub-scale, single-chemistry commodity-to-semi-specialty producer whose earnings are driven by the spread between MCA/derivative realisations and acetic acid/chlorine costs, plus utilisation of a capacity base that was roughly tripled by the Bhavnagar project in FY2018. Profitability has been highly cyclical (operating margin of –4% in FY2019, 15% in FY2023, 6% in FY2024 and 12% in FY2026 per Screener). Exports, which reached ~26% of product revenue in FY2022, have retreated to ~13%, suggesting that international competitiveness weakened as Chinese supply normalised and as the large Anaven plant (32,000 tpa, commissioned 2020-21) reshaped the Indian market. The company's most important strategic question in late 2026 is not organic — it is whether the promoter-group transaction with Archit Life Science Limited proceeds, on what terms, and with what dilution.
Strategy
Stated strategy themes
The company does not publish investor presentations, investor-day materials or earnings-call transcripts. Stated themes, from the FY2026 Directors' Report as summarised by ScanX and earlier offering documents, are:
-
Capturing the specialty-chemicals opportunity — the board cited confidence based on India's specialty-chemicals growth and expanding export markets.
-
Technology absorption and energy conservation — maintained as a competitive lever (statutory disclosure theme).
-
Moving up the value chain — the Bhavnagar project's explicit rationale was adding higher-value CAC/TCAC to MCA/SMCA and broadening the Indian customer base in agrochemicals, pharmaceuticals and water treatment (SEBI DLoF 2016).
-
Vertical integration via Archit Life Science — the proposed 67.44% ALS acquisition was framed as strengthening the company's position in the chemical industry through vertical integration (ScanX, Sep 2026).
Initiatives in the last 24 months (Oct 2024 – Oct 2026)
| Initiative | Date | Description | Status | Source |
|---|---|---|---|---|
| Promoter land acquisition, Bhavnagar | Board approval 21 Feb 2026; Banakhat 17 Mar 2026 | Purchase of land from Chairman Kandarp Amin for INR 10.51 Cr | Agreement executed; completion status not disclosed | ScanX |
| Preferential issue & authorised capital increase | Board 3 Sep 2026 | Issue of equity on preferential basis (consideration other than cash) and higher authorised capital | Withdrawn from AGM 23 Sep 2026 for restructuring; BSE in-principle approval pending | Sharekhan; Multibagg |
| Acquisition of 67.44% of Archit Life Science Ltd | Announced with AGM notice, Sep 2026 | 1,36,24,172 ALS shares via share swap valued ≈INR 177.11 Cr | Withdrawn for restructuring | ScanX; Multibagg |
| Related-party framework with ALS | AGM 2026 | Approvals sought for loans up to INR 75 Cr and trade transactions up to INR 100 Cr p.a. for FY2027 and FY2028 | Outcome per AGM results not captured | ScanX |
| Dividend step-up | 16 May 2026 | Final dividend raised to ₹1.00 from ₹0.50 | Approved at AGM (record date set 3 Sep 2026) | ScanX; Sharekhan |
| KMP refresh | FY2026 | New CFO (Anilkumar G. Patel) and CS (Chirag Chouhan) | Completed | ScanX |
ESG commitments, cost programs, medium-term targets
ESG/sustainability commitments: None publicly disclosed (no BRSR is mandated for a company of this size; no targets found).
Cost programmes with targets: None disclosed.
Medium-term financial guidance: Not publicly disclosed. The company does not issue guidance and has zero analyst coverage (Simply Wall St).
Analyst view. In practice, strategy is promoter-led and transactional: the largest strategic act of 2026 is not organic capacity but a proposed reverse-integration of a promoter-held entity (ALS) whose implied 100% valuation (~INR 263 Cr, derived from INR 177.11 Cr for 67.44%) is roughly double Archit Organosys's own market capitalisation.
Products & Services
All products sit within the single Chemicals & Organics segment.
Monochloroacetic Acid (MCA / MCAA)
Description: Chlorinated acetic acid (ClCH₂COOH), the platform molecule of the portfolio.
Capabilities/specs: Produced at both Naroda (historically 6,000 MTPA) and Bhavnagar (designed 12,000 MTPA). Purity grades and product forms (flakes/molten/crystal) not specified in reviewed sources.
Target customers: Agrochemical (2,4-D), pharma intermediates, CMC producers, surfactant makers.
Launch: Core product since 1989.
Pricing: Market-linked; not disclosed.
Flagship status: Yes — the company's anchor product.
Sodium Monochloroacetate (SMCA)
Description: Sodium salt of MCA, preferred by CMC and surfactant producers for handling and safety.
Specs: Historical capacity 1,800 MTPA (Naroda) plus 2,400 MTPA designed at Bhavnagar. The company developed an in-house SMCA crystal form (from powder), claimed as a first in the Indian market and credited to Whole-Time Director Archit Amin (Jeena Scriptech, 2017).
Target customers: CMC (oil drilling, food, detergent), betaine surfactants.
Launch: Original product; crystal form c. 2017.
Chloroacetyl Chloride (CAC)
Description: Higher-value acid chloride (ClCH₂COCl) used as an acylating agent.
Specs: 3,000 MTPA designed capacity at Bhavnagar (shared with "SBS" per the rights-issue offer document).
Target customers: Pharma (diclofenac/aceclofenac routes, lidocaine-class anaesthetics), agrochemicals (chloroacetanilide herbicides).
Launch: FY2017-18 with Bhavnagar.
Positioning: ICRA described it as a higher value-added product than MCA.
Trichloroacetyl Chloride (TCAC)
Description: Further-chlorinated acid chloride.
Specs: Capacity not disclosed; listed among developed products (MarketScreener; IIFL). The FY2017-18 annual report allocates rights-issue funds to "MCA, TCAC, SBS, CAC Unit" technology upgradation.
Target customers: Agro/pharma intermediate synthesis.
SBS (as named in offering documents)
Description: Product grouped with CAC in the Bhavnagar plan; chemical identity not expanded in reviewed sources.
Status: Not publicly detailed.
Polyaluminium Chloride (PAC) — planned
Description: Water-treatment coagulant, typically a co-product route for HCl by-product.
Status: Listed in the 2016 rights offer as a product the Bhavnagar facility "will add"; commercial production not confirmed in later sources.
Organic Pigments and Specialty Derivatives
Description: Pigments and specialty derivatives cited in company and S&P descriptions.
Details: Specific shade/chemistry families not disclosed.
AOL Adhesives & Sealants
Description: Branded range of sealants sold under the "AOL®" mark (the company's letterhead carries AOL®).
Details: Product names, channel and revenue share not disclosed; entry described on Screener's key-points summary and S&P profile.
Traded Products
Description: Trading of organic and specialty chemicals including ethyl acetate, acetic anhydride and toluene (ICRA 2017).
Trend: ScanX's reading of FY2026 results notes a sharp shift from raw-material consumption to purchases of stock-in-trade, suggesting trading grew materially in FY2026.
Downstream application map
| Product | Pharma | Agro | Oilfield/CMC | Surfactants/Cosmetics | Pigments | Water treatment |
|---|---|---|---|---|---|---|
| MCA | Yes | Yes | Yes | Yes | Yes | No |
| SMCA | No | Limited | Yes | Yes | No | No |
| CAC | Yes | Yes | No | No | No | No |
| TCAC | Yes | Yes | No | No | No | No |
| PAC (planned) | No | No | No | No | No | Yes |
Financial Narrative
Source for all tables in this section: S&P Global Market Intelligence via StockAnalysis.com (standardized; standalone), last updated 12 Aug 2026, cross-checked with Screener (C-MOTS) and company results releases. Units: INR M unless stated.
Income statement
Notes: (i) S&P's "gross profit" deducts only material costs; power, fuel, employee and other manufacturing costs sit in "other operating expenses", so gross margin overstates true manufacturing gross margin. (ii) Company-reported FY2026: total income INR 14,383.71 lakh, PBT INR 1,099.25 lakh, PAT INR 803.21 lakh, finance cost INR 228.82 lakh, depreciation INR 601.44 lakh (ScanX). (iii) Dividend mapping uses Screener payout ratios (FY2022 19%, FY2023 9%, FY2025 20%, FY2026 26%) and declared amounts; S&P/SA's dividend-by-fiscal row is offset by one period in places.
Margins and growth
Revenue CAGR: FY2022→FY2026 (4-year) ≈ 0.8% p.a.; FY2023→FY2026 (3-year) ≈ 3.3% p.a. Screener cites 5-year sales CAGR of 8% and 10-year 11% (standalone, from a lower FY2021 base of INR 95 Cr).
Commentary — income statement. The five-year arc is a classic commodity cycle layered over a capacity step-up. FY2022 saw revenue surge 44.6% on post-pandemic restocking and elevated chemical prices, with exports at their peak. FY2023 delivered the best margins of the period (gross margin 39.2%, EBITDA margin 15.3%) despite lower volumes — spread-driven, as feedstock costs eased faster than MCA realisations. FY2024 was the inflection down: revenue fell 11.4% and gross margin compressed ~880 bp, while depreciation stepped up as the expansion was capitalised, crushing EBIT margin to 1.2%. Reported FY2024 net income (INR 33.4 M) was flattered by non-operating items: S&P classifies INR 59.24 M of "other unusual items" and a ~INR 57.6 M gain on asset sales (cash-flow statement) against a INR 25.05 M charge S&P labels "legal settlements" — so underlying FY2024 pre-tax earnings excluding unusual items were only INR 5.0 M. FY2025 and FY2026 show a measured recovery driven by volume (+11–12% revenue) rather than spread (gross margin flat at ~29–30%), with operating leverage lifting EBIT margin to 7.5%. The FY2026 earnings jump of 59% also benefited from a lower tax rate (26.9% vs 33.0%) and lower finance costs. Q1 FY2027, however, showed margin pressure (net profit –29% YoY on revenue +11.7%), signalling the recovery is not yet secure.
Five-year view with FY2021 baseline (Screener, INR Cr, standalone)
Discrepancy note: Screener shows FY2023 EPS of ₹5.57 vs S&P ₹5.53; FY2022 sales INR 138 Cr vs S&P INR 136.7 Cr — rounding and classification of other operating revenue.
Balance sheet
Debt split (FY2026): short-term (working-capital borrowings + current maturities + current leases) INR 220.63 M (88% of total); long-term (term debt + non-current leases) INR 30.77 M (12%).
Commentary — balance sheet. Two trends dominate. First, term debt has been steadily repaid — long-term debt including current maturities fell from INR 205.8 M (FY2022) to INR 59.7 M (FY2026) — while short-term working-capital debt rose from INR 115 M to INR 187 M, shifting the funding mix toward revolving bank lines. Second, and more analytically significant, non-trade receivables ballooned: total receivables minus trade receivables rose from ~INR 1 M in FY2023 to ~INR 329 M in FY2025 and ~INR 293 M in FY2026 — about 38–40% of equity — coinciding with an INR 199.7 M "other investing" outflow in FY2025. The nature of these balances (loans/advances, and to whom) is not explained in reviewed sources; given that the September 2026 AGM sought approval for loans of up to INR 75 Cr to Archit Life Science, a related-party character is plausible but unconfirmed. Separately, other long-term assets jumped to INR 90.5 M in FY2026, broadly consistent with an advance against the INR 10.51 Cr promoter land purchase (inference, not confirmed). Net PP&E is declining as depreciation outruns maintenance capex (INR 5–16 M p.a. since FY2024). There is no goodwill; tangible book equals reported book.
Cash flow
Commentary — cash flow. FY2022–FY2023 were investment years (INR 269 M cumulative capex for the 6,000 MTPA expansion), absorbing nearly all operating cash. FY2024–FY2025 were harvest years: capex collapsed and working-capital release drove FCF to INR 85.8 M and INR 180.2 M. However, FY2025's strong FCF was redeployed not into debt reduction but into the ~INR 200 M "other investing" outflow noted above, which is why cash fell to INR 4 M and net debt rose. In FY2026, OCF collapsed to INR 26.9 M (CFO/EBITDA 29% per Screener vs 150% in FY2025) because receivables rose INR 112.8 M — a quality-of-earnings flag for a year in which reported profit rose 59%. Partial recovery of investing balances (+INR 63.5 M) funded debt repayment and the dividend.
Returns, leverage and efficiency ratios
Interest coverage computed by the analyst from S&P EBIT and interest expense. Screener reports ROCE of 18%, 17%, 4%, 11%, 14% for FY2022–FY2026 (methodology differences).
Commentary — ratios. Returns peaked at ~20% ROE in FY2023 and remain below the cost of equity for an Indian micro-cap (roughly 13–15%) in FY2024–FY2026; Screener's 3-year average ROE is 6.8% and MarketsMojo cites an average ROCE of ~10%. Leverage has improved structurally (D/E 0.66→0.33) and coverage recovered to ~4.9x. The operating cycle is short (low inventory days reflect continuous-process chemistry and trading flow-through), but the cash conversion cycle is sensitive to supplier credit, which swung from 110 to 62 to 91 to 65 days — a sign that payables, not structural efficiency, explain much of the working-capital volatility.
Quarterly trajectory (Screener, standalone, INR Cr)
The trough was Q3–Q4 FY2024 (OPM ~1–4%; Q4 profit propped by INR 4.11 Cr other income). Margins rebuilt to 12–13% by Q3–Q4 FY2026 before slipping to 9.1% in Q1 FY2027.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Results by Segment and Segment Margins & Growth (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Segment revenue — Chemicals & Organics (INR Mn) | 1,367 | 1,278 | 1,132 | 1,257 | 1,410 |
Segment operating income / EBIT (INR Mn) | 124.36 | 153.24 | 13.81 | 71.71 | 106.33 |
Segment pre-tax income (INR Mn) | 114.25 | 153.58 | 43.87 | 75.39 | 109.93 |
Segment EBIT margin (%) | 9.10 | 11.99 | 1.22 | 5.71 | 7.54 |
Segment revenue YoY growth (%) | 44.60 | -6.50 | -11.42 | 11.03 | 12.16 |
Contribution to total revenue (%) | 100 | 100 | 100 | 100 | 100 |
Group Entities
| Entity | Relationship | Jurisdiction | Status |
|---|---|---|---|
Archit Organosys Limited | Listed parent | India | Operating |
Shri Chlochem Global FZE | Wholly owned subsidiary (est. FY2005-06) | Ras Al Khaimah, UAE | Current status not publicly confirmed; no consolidated accounts referencing it in recent years were reviewed |
Archit Life Science Limited ("ALS") | Incorporated 2023 as WOS; by Sep 2026 the company proposed acquiring 67.44% (1,36,24,172 shares), implying that ALS's capital is now predominantly held outside the company — most likely by promoter-group parties, given the transaction was classified as a material related-party transaction | India | Proposed acquisition withdrawn 23 Sep 2026 for restructuring |
Archit Polymers Pvt. Ltd. | Promoter-group associate (Archit Group) | India | Not a subsidiary |
Income Statement and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue (INR Mn) | 1,367 | 1,278 | 1,132 | 1,257 | 1,410 |
Cost of revenue (INR Mn) | 959.52 | 776.99 | 788.21 | 882.51 | 995.56 |
Gross profit (INR Mn) | 407.12 | 500.84 | 343.70 | 374.20 | 413.96 |
SG&A (INR Mn) | 66.54 | 76.35 | 63.24 | 76.34 | 77.89 |
Other operating expenses (INR Mn) | 169.36 | 222.45 | 210.06 | 166.73 | 169.60 |
EBITDA (INR Mn) | 164.56 | 195.94 | 68.59 | 129.24 | 164.59 |
Operating income / EBIT (INR Mn) | 124.36 | 153.24 | 13.81 | 71.71 | 106.33 |
Interest expense (INR Mn) | 24.45 | 20.92 | 24.59 | 24.76 | 21.75 |
Pre-tax income (INR Mn) | 114.25 | 153.58 | 43.87 | 75.39 | 109.93 |
Income tax (INR Mn) | 31.94 | 40.09 | 10.49 | 24.88 | 29.60 |
Net income (INR Mn) | 82.32 | 113.49 | 33.38 | 50.51 | 80.32 |
EPS basic (INR) | 4.01 | 5.53 | 1.63 | 2.46 | 3.91 |
EPS diluted (INR) | 4.01 | 5.53 | 1.63 | 2.46 | 3.91 |
Dividend per share declared for year (INR) | 0.75 | 0.50 | 0 | 0.50 | 1.00 |
Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Gross margin (%) | 29.79 | 39.20 | 30.36 | 29.78 | 29.37 |
EBITDA margin (%) | 12.04 | 15.33 | 6.06 | 10.28 | 11.68 |
Operating margin (%) | 9.10 | 11.99 | 1.22 | 5.71 | 7.54 |
Pre-tax margin (%) | 8.36 | 12.02 | 3.88 | 6.00 | 7.80 |
Net margin (%) | 6.02 | 8.88 | 2.95 | 4.02 | 5.70 |
Effective tax rate (%) | 27.95 | 26.10 | 23.91 | 33.00 | 26.93 |
Revenue growth (%) | 44.60 | -6.50 | -11.42 | 11.03 | 12.16 |
Net income growth (%) | 64.42 | 37.87 | -70.59 | 51.33 | 59.02 |
Income Statement and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|
Sales (INR Cr) | 95 | 138 | 128 | 113 | 126 | 141 |
Operating profit excl. other income (INR Cr) | 11 | 17 | 20 | 7 | 13 | 17 |
OPM (%) | 12 | 12 | 15 | 6 | 10 | 12 |
Other income (INR Cr) | 0 | 1 | 3 | 6 | 3 | 3 |
Interest (INR Cr) | 3 | 2 | 2 | 3 | 3 | 2 |
Depreciation (INR Cr) | 4 | 5 | 5 | 6 | 6 | 6 |
PBT (INR Cr) | 5 | 11 | 15 | 4 | 8 | 11 |
Net profit (INR Cr) | 5 | 8 | 11 | 3 | 5 | 8 |
EPS (INR) | 3.34 | 4.01 | 5.57 | 1.63 | 2.46 | 3.91 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansBalance Sheet and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets (INR Mn) | 1,036 | 1,202 | 1,082 | 1,229 | 1,267 |
Cash & equivalents (INR Mn) | 53.50 | 53.80 | 42.20 | 4.03 | 22.46 |
Trade receivables (INR Mn) | 273.53 | 373.56 | 222.33 | 230.48 | 245.48 |
Total receivables incl. other (INR Mn) | 306.53 | 374.74 | 324.85 | 559.44 | 538.23 |
Inventory (INR Mn) | 59.37 | 33.81 | 34.45 | 43.02 | 29.51 |
Total current assets (INR Mn) | 429.28 | 479.44 | 414.84 | 614.96 | 609.20 |
Net PP&E (INR Mn) | 578.00 | 668.77 | 603.59 | 547.75 | 498.48 |
Construction in progress (INR Mn) | 127.46 | 164.19 | 7.02 | 8.06 | 0 |
Long-term investments (INR Mn) | 14.00 | 36.45 | 58.72 | 63.44 | 68.55 |
Other long-term assets (INR Mn) | 14.26 | 17.08 | 5.19 | 3.03 | 90.49 |
Goodwill & intangibles (INR Mn) | 0 | 0 | 0 | 0 | 0 |
Accounts payable (INR Mn) | 135.58 | 231.89 | 132.62 | 217.92 | 174.89 |
Short-term borrowings (INR Mn) | 115.43 | 114.56 | 135.64 | 190.37 | 186.92 |
Current portion of LT debt (INR Mn) | 83.68 | 52.95 | 44.70 | 34.27 | 31.65 |
Long-term debt (INR Mn) | 122.10 | 141.98 | 76.29 | 44.88 | 28.07 |
Lease liabilities total (INR Mn) | 18.48 | 4.59 | 7.83 | 6.45 | 4.76 |
Total debt incl. leases (INR Mn) | 339.69 | 314.09 | 264.45 | 275.97 | 251.40 |
Net debt (INR Mn) | 286.20 | 260.28 | 222.25 | 271.95 | 228.94 |
Total liabilities (INR Mn) | 516.61 | 583.99 | 440.87 | 537.13 | 504.39 |
Shareholders' equity (INR Mn) | 518.93 | 617.76 | 641.46 | 692.06 | 762.33 |
Working capital (INR Mn) | 53.23 | 60.40 | 72.22 | 157.95 | 177.04 |
Book value per share (INR) | 25.29 | 30.10 | 31.26 | 33.72 | 37.15 |
Cash Flow and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow (INR Mn) | 106.22 | 172.42 | 101.95 | 185.20 | 26.85 |
Change in working capital (INR Mn) | -56.98 | 4.88 | 56.09 | 66.16 | -117.27 |
Capital expenditure (INR Mn) | -108.40 | -160.23 | -16.11 | -4.98 | -12.45 |
Free cash flow (INR Mn) | -2.18 | 12.19 | 85.84 | 180.23 | 14.40 |
Proceeds from asset sales (INR Mn) | 1.00 | 43.94 | 64.76 | 1.38 | 0 |
Other investing incl. loans (INR Mn) | 3.24 | 27.26 | -53.41 | -199.68 | 63.52 |
Investing cash flow (INR Mn) | -115.16 | -107.03 | -22.56 | -208.47 | 43.93 |
Net debt issued / (repaid) (INR Mn) | 15.46 | -25.59 | -54.35 | 10.93 | -25.15 |
Equity issued (INR Mn) | 41.25 | 0 | 0 | 0 | 0 |
Dividends paid (INR Mn) | -10.26 | -14.38 | -9.85 | -0.01 | -10.26 |
Share buybacks (INR Mn) | 0 | 0 | 0 | 0 | 0 |
Cash interest paid (INR Mn) | 22.11 | 25.69 | 27.15 | 25.20 | 22.30 |
Cash taxes paid (INR Mn) | 14.66 | 31.47 | 10.42 | 9.66 | 22.05 |
FCF margin (%) | -0.16 | 0.95 | 7.58 | 14.34 | 1.02 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE (%) | 17.81 | 19.97 | 5.30 | 7.58 | 11.04 |
ROA (%) | 8.14 | 8.56 | 0.76 | 3.88 | 5.33 |
ROIC (%) | 12.11 | 13.46 | 1.21 | 5.26 | 7.95 |
ROCE (%) | 18.90 | 19.60 | 1.90 | 9.30 | 12.70 |
Current ratio (x) | 1.14 | 1.14 | 1.21 | 1.35 | 1.41 |
Quick ratio (x) | 0.90 | 1.02 | 0.78 | 0.51 | 0.62 |
Debt / equity (x) | 0.66 | 0.51 | 0.41 | 0.40 | 0.33 |
Net debt / equity (x) | 0.55 | 0.42 | 0.35 | 0.39 | 0.30 |
Net debt / EBITDA (x) | 1.74 | 1.33 | 3.24 | 2.10 | 1.39 |
Interest coverage EBIT/interest (x) | 5.09 | 7.33 | 0.56 | 2.90 | 4.89 |
Asset turnover (x) | 1.43 | 1.14 | 0.99 | 1.09 | 1.13 |
Inventory turnover (x) | 20.25 | 16.68 | 23.10 | 22.79 | 27.46 |
Debtor days (Screener) | 72 | 107 | 72 | 67 | 64 |
Inventory days (Screener) | 22 | 16 | 16 | 18 | 11 |
Payable days (Screener) | 51 | 110 | 62 | 91 | 65 |
Cash conversion cycle days (Screener) | 44 | 13 | 26 | -6 | 10 |
Income Statement and Margin Analysis (%) (Quarterly)
| Metric | Q1FY24 | Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sales (INR Cr) | 31.00 | 26.39 | 24.81 | 30.99 | 27.00 | 29.54 | 25.87 | 43.18 | 33.20 | 32.86 | 38.40 | 36.50 | 37.08 |
Operating profit (INR Cr) | 3.24 | 2.11 | 1.10 | 0.29 | 3.05 | 2.85 | 2.66 | 4.42 | 4.14 | 2.70 | 4.68 | 4.89 | 3.37 |
OPM (%) | 10.45 | 8.00 | 4.43 | 0.94 | 11.30 | 9.65 | 10.28 | 10.24 | 12.47 | 8.22 | 12.19 | 13.40 | 9.09 |
Other income (INR Cr) | 0.71 | 0.54 | 0.52 | 4.11 | 0.47 | 0.63 | 0.93 | 1.06 | 1.00 | 1.46 | 0.90 | -0.47 | 0.60 |
PBT (INR Cr) | 2.24 | 0.51 | -0.64 | 2.28 | 1.41 | 1.20 | 1.63 | 3.31 | 3.05 | 1.97 | 3.50 | 2.47 | 2.03 |
Net profit (INR Cr) | 1.64 | 0.37 | -0.46 | 1.79 | 1.01 | 1.02 | 1.01 | 2.02 | 2.04 | 1.54 | 2.43 | 2.02 | 1.45 |
EPS (INR) | 0.80 | 0.18 | -0.22 | 0.87 | 0.49 | 0.50 | 0.49 | 0.98 | 0.99 | 0.75 | 1.18 | 0.98 | 0.71 |
Revenue by Region
| Region | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
India (INR Mn) | 1,012 | 1,032 | 972.98 | 1,016 | 1,166 |
Rest of the World (INR Mn) | 353.08 | 178.18 | 130.53 | 172.96 | 169.06 |
Total geographic (INR Mn) | 1,365 | 1,210 | 1,104 | 1,189 | 1,335 |
Region Margins & Growth (%) and Revenue by Region (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
India YoY growth (%) | 0 | 2.0 | -5.7 | 4.4 | 14.8 |
Rest of World YoY growth (%) | 0 | -49.5 | -26.7 | 32.5 | -2.3 |
India share (%) | 74.1 | 85.3 | 88.2 | 85.5 | 87.3 |
Rest of World share (%) | 25.9 | 14.7 | 11.8 | 14.5 | 12.7 |
Share Price & Returns
| Horizon | Return (%) | Source |
|---|---|---|
1 year | 31 | Screener (stock price CAGR) |
3 years (CAGR) | 3 | Screener |
5 years (CAGR) | 6 | Screener |
10 years (CAGR) | 8 | Screener |
6 months | 35.1 | ScanX |
Capital Markets Data (INR) and Market Valuation
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Fiscal year-end close (INR, adjusted) | 37.29 | 58.33 | 42.18 | 36.46 | 35.62 |
Market capitalisation (INR Mn) | 801 | 1,239 | 888 | 767 | 742 |
Enterprise value (INR Mn) | 1,021 | 1,598 | 1,182 | 1,073 | 1,022 |
P/E (x) | 9.74 | 10.92 | 26.60 | 15.19 | 9.24 |
EV/EBITDA (x) | 6.20 | 8.15 | 17.23 | 8.30 | 6.21 |
EV/Sales (x) | 0.75 | 1.25 | 1.04 | 0.85 | 0.73 |
P/B (x) | 1.54 | 2.01 | 1.38 | 1.11 | 0.97 |
Dividend yield (%) | 1.92 | 0.83 | 0 | 1.34 | 2.77 |
Valuation Multiples
| Multiple | Archit Organosys | Source |
|---|---|---|
Price | ₹61.1–61.5 | Screener; S&P/SA |
Market cap | ≈INR 1,250–1,261 M | Screener; S&P/SA |
P/E (TTM) | 16.8–17.2x | Screener; S&P/SA |
EV/EBITDA | 9.6x | S&P/SA |
EV/Sales | 1.04x | S&P/SA |
P/B | 1.64–1.68x | Screener; S&P/SA |
Dividend yield | 1.63–1.64% | S&P/SA; Screener |
Per-Share Data and Returns & Leverage Ratios (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|
Dividend per share (INR) | 0.50 | 0.75 | 0.50 | 0 | 0.50 | 1.00 |
Payout ratio (%) | 15 | 19 | 9 | 0 | 20 | 26 |
Analyst Conclusions
Management guidance and consensus
There is no management guidance and no consensus estimates. The board's qualitative outlook (FY2026 Directors' Report) expresses confidence based on specialty-chemical demand and export markets. Run-rate analysis: Q1 FY2027 revenue of INR 37.08 Cr annualises to ~INR 148 Cr (+5% vs FY2026), but at Q1's 9.1% OPM, FY2027 PAT would be closer to INR 6–7 Cr than FY2026's INR 8.0 Cr absent margin recovery — an analyst illustration, not a forecast.
Bull case
-
Operating leverage on installed capacity: with capex at maintenance levels (INR 12.5 M in FY2026) and capacity already capitalised, a return to FY2023-type spreads (EBITDA margin 15%) on FY2026 revenue would lift EBITDA to ~INR 210 M, with most of it converting to FCF.
-
Balance-sheet repair continues: D/E 0.33x and net debt/EBITDA 1.39x leave room for higher payouts or growth investment; the dividend has already doubled.
-
Accretive restructuring of ALS: if the restructured transaction is priced fairly and brings genuine vertical integration and scale, Archit could re-rate from a sub-scale commodity producer to a larger integrated intermediates platform.
Bear case
-
Structural competitive squeeze: Anaven's capacity (and expansion option to 60,000 tpa) and Chinese supply cap MCA spreads; exports have already halved since FY2022 and Q1 FY2027 profits fell 29%.
-
Governance and dilution: a ≈INR 177 Cr related-party swap against a ~INR 125 Cr market cap could more than double the share count and transfer value to promoters if ALS is overvalued; the promoter land purchase and up to INR 75 Cr loan approvals add to RPT intensity.
-
Earnings quality: FY2026 profit growth coincided with an 85% drop in operating cash flow and ~INR 290 M of unexplained non-trade receivables, suggesting reported earnings overstate distributable cash.
Catalysts and monitorables (next 12 months)
| Catalyst / monitorable | Expected timing | Why it matters |
|---|---|---|
| Q2 FY2027 results | Board meeting likely Nov 2026 | Tests whether Q1 margin dip is transient |
| Re-filed ALS transaction terms (valuation, swap ratio, independent valuer, ALS financials) | Unspecified | Determines dilution and governance trajectory |
| BSE in-principle approval for preferential issue | Pending | Gating item for any restructured deal |
| Completion of promoter land purchase | 2026-27 | RPT execution and capex plans |
| Nature and recovery of non-trade receivables/loans | FY2027 interim balance sheets | Earnings/cash quality |
| India Ratings next review | Periodic | Credit trajectory |
| MCA/acetic acid price trends; Anaven expansion | Ongoing | Spread outlook |
| Export revenue trend | Quarterly segment notes | Competitiveness |
| Promoter holding changes | Quarterly | Control/float dynamics |
Concluding analyst verdict
Archit Organosys is a genuine but small operating business — a 35-year-old chloroacetyl chemistry franchise with two Gujarat plants, credible process know-how, and a product ladder from MCA through SMCA to CAC and TCAC. The FY2024–FY2026 recovery is real at the P&L level: revenue regained INR 1.41 B, EBITDA margin rebuilt to 11.7%, net income more than doubled from the trough, leverage fell to a comfortable 0.33x debt-to-equity, and the dividend doubled. At ~17x trailing earnings and ~9.6x EV/EBITDA, the stock is no longer the deep-value situation it was at FY2026 year-end (9x P/E, below book), having re-rated ~35% over six months.
The difficulty is that the forward thesis is now dominated less by chemistry than by capital allocation. Three facts weigh heavily: first, operating cash flow collapsed to INR 27 M in a year of record-since-FY2023 profits; second, roughly INR 290–330 M of non-trade receivables appeared on the balance sheet across FY2025–FY2026 without public explanation; third, management proposed — then withdrew for restructuring — a ≈INR 177 Cr related-party share swap for 67.44% of Archit Life Science that would dwarf the company's own market value. Layered on a promoter land purchase and pre-approved inter-company loan and trade limits, this creates a material risk that minority shareholders bear dilution and related-party exposure without commensurate value transfer.
The competitive backdrop is also unforgiving: the Nouryon–Atul Anaven plant alone exceeds Archit's MCA capacity, exports have halved since FY2022, and Q1 FY2027 already shows margin slippage.
Verdict: Neutral-to-cautious. The operating recovery supports intrinsic value around current levels, but the risk-reward is asymmetric to the downside until the ALS transaction is re-presented with transparent valuation, independent fairness opinions and ALS financials, and until cash conversion normalises. Investors should treat disclosure of the restructured deal terms and the H1 FY2027 balance sheet as the decisive monitorables.
APPENDIX — SOURCES
-
StockAnalysis.com (S&P Global Market Intelligence data): https://stockanalysis.com/quote/bom/524640/financials/ ; /balance-sheet/ ; /cash-flow-statement/ ; /ratios/ ; /income-statement/ ; /company/
-
Screener.in — Archit Organosys Ltd: https://www.screener.in/company/524640/
-
ScanX (Dhan) — FY2026 results and AGM proposals: https://scanx.trade/stock-market-news/companies/archit-organosys-net-profit-rises-59-803-21-lakh-fy26/50355194
-
ScanX — Promoter land purchase INR 10.51 Cr: https://scanx.trade/stock-market-news/companies/archit-organosys-limited-purchases-land-from-promoter-for-rs-10-51-crore/35301309
-
ScanX — Q1 FY2027 results / fund-raise board meeting: https://scanx.trade/stock-market-news/companies/archit-organosys-consider-fund-raise-board-meeting/49389910
-
ScanX — FY2026 results/auditor: https://scanx.trade/stock-market-news/companies/archit-organosys-schedules-board-meeting-on-may-16-2026-to-approve-q4fy26-audited-financial-results/40032375
-
ScanX — Reg 74(5) and promoter purchase: https://scanx.trade/stock-market-news/companies/archit-organosys-limited-submits-sebi-compliance-certificate-for-q4fy26/37656022
-
ScanX company page: https://scanx.trade/company/archit-organosys-ltd
-
Multibagg — AGM withdrawal details: https://www.multibagg.ai/market-pulse/articles/archit-organosys-q1-results-aug12-cmufm7k0x000g2uo6fccpo3h9
-
Multibagg — Preferential issue board meeting: https://www.multibagg.ai/market-pulse/articles/archit-organosys-board-preferential-issue-cmtljt618000f2orhnbzb7y3r
-
Whalesbook — AGM items withdrawn: https://www.whalesbook.com/corporate-news/English/chemicals/Archit-Organosys-Withdraws-AGM-Agenda-Items-Including-Archit-Life-Science-Acquisition/6ab3d26bf2017017ae719c33
-
Sharekhan — company news: https://www.sharekhan.com/stock/archit-organosys-ltd
-
Business Standard (Capital Market Live) — Q1 FY2026 and Q4 FY2025 results: https://www.business-standard.com/markets/capital-market-news/archit-organosys-standalone-net-profit-rises-101-98-in-the-june-2025-quarter-125081400287_1.html ; https://www.business-standard.com/markets/capital-market-news/archit-organosys-standalone-net-profit-rises-12-85-in-the-march-2025-quarter-125052400152_1.html
-
Emkay/Dion Global — Q2 FY2026 and news feed: https://www.emkayglobal.com/news-details/eod/4555939 ; https://www.emkayglobal.com/company-info/company-news/archit-organosys-ltd
-
BSE filings (via Business Standard media): Feb 2025 board outcome; May 2025 audited results; May 2025 secretarial compliance; May 2023 board outcome
-
ICRA rationales: https://www.icra.in/Rating/ShowRationalReportFilePdf/62580 ; https://www.icra.in/Rating/GetRationalReportFilePdf?Id=28705 ; https://www.icra.in/Rating/GetRationalReportFilePdf?id=78588
-
SEBI Draft Letter of Offer (2016): https://www.sebi.gov.in/sebi_data/attachdocs/1477300737440.pdf
-
Annual Report FY2017-18: https://www.architorg.com/investorrelations/Financials/annualreport/For%20the%20Financial%20Year%20ended%20on%20%2031.03.2018.pdf
-
Annual Reports 2012, 2014, 2017 (BSE archive)
-
Simply Wall St — management and overview: https://simplywall.st/stocks/in/materials/bse-524640/archit-organosys-shares/management
-
TradingView: https://in.tradingview.com/symbols/BSE-ARCHITORG
-
MarketScreener: https://www.marketscreener.com/quote/stock/ARCHIT-ORGANOSYS-LIMITED-20705366/company/
-
GuruFocus: https://www.gurufocus.com/stock/BOM:524640/summary
-
Trendlyne shareholding: https://client.trendlyne.com/equity/share-holding/3062/ARCHITORG/30-06-2023/archit-organosys-ltd
-
IIFL company summary: https://www.indiainfoline.com/company/archit-organosys-ltd/summary
-
Kotak Securities: https://kotaksecurities.com/stocks/archit-organosys-ltd
-
ICICIdirect: https://www.icicidirect.com/stocks/archit-organosys-ltd-share-price
-
EnrichMoney (management): https://enrichmoney.in/orca/stock-analysis/archit-organosys-company-details
-
BFSL/Vogue (KMP, RTA): https://voguestock.in/fundamental/livequotes/archit-organosys-ltd
-
Equitymaster: https://www.equitymaster.com/share-price/SCHO/524640/ARCHIT-ORGANOSYS-LTD-Share-Price
-
Tickertape: https://www.tickertape.in/stocks/archit-organosys-ARCH
-
Fyers peer table: https://fyers.in/stocks/archit-organosys-ltd/results
-
Jeena Scriptech (2017): https://jsalphaa.com/archit-organosys-ltd/
-
Fuels & Lubes — Standard Greases stake: https://www.fuelsandlubes.com/standard-greases-acquires-small-stake-in-archit-organosys/
-
MarketsMojo rating changes: https://www.marketsmojo.com/news/stock-recommendation/archit-organosys-ltd-downgraded-to-sell-amid-mixed-fundamentals-and-technical-signals-4207809
-
Global Market Insights — MCA market: https://gminsights.com/industry-analysis/monochloroacetic-acid-MCAA-market/amp
-
Nouryon/Anaven: https://www.sofw.com/de/news/latest-news/general/2148-nouryon-and-atul-partner-to-supply-fast-growing-indian-markets ; https://cosmetics.specialchem.com/news/industry-news/anaven-receives-environmental-clearance-to-expand-mca-production-in-india-000223093
-
MarketsandMarkets — MCA industry structure: https://www.marketsandmarkets.com/ResearchInsight/monochloroacetic-acid-market.asp
-
IMARC — MCA cost structure: https://www.imarcgroup.com/chloroacetic-acid-manufacturing-plant-project-report
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Title | Tenure / appointment | Background | Source |
|---|---|---|---|---|
Kandarp Krishnakant Amin (DIN 00038972) | Chairman & Whole-Time Director; treated as CEO | WTD since 22 Jan 2000 (~26 years); retires by rotation and offered re-appointment at 2026 AGM | Founder-promoter of Archit Group; education/age not disclosed in reviewed sources | Simply Wall St; ScanX |
Archana Kandarp Amin | Whole-Time Director | On board since at least FY2013-14 | Promoter; age/education not disclosed | AR 2013-14; EnrichMoney |
Archit Kandarp Amin (DIN 01681638) | Whole-Time Director | Additional Director 12 May 2017, then WTD | Educated in the USA; credited with developing crystalline SMCA | AR 2016-17; Jeena Scriptech |
Shreeraj Desai | Non-Executive Independent Director | — | — | EnrichMoney |
Nikul Patel | Non-Executive Independent Director | — | — | EnrichMoney |
Bhavin Shah | Non-Executive Independent Director | — | — | EnrichMoney |
Vatsal S. Vora | Non-Executive Independent Director | — | — | EnrichMoney |
Anilkumar G. Patel | Chief Financial Officer | Appointed during FY2026 | — | ScanX; BFSL |
Chirag Chouhan | Company Secretary & Compliance Officer | Appointed during FY2026 | — | ScanX; BFSL |
“—” = not publicly disclosed.
Executive Leadership Team
| Executive | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Kandarp Amin total compensation (INR Mn) | 8 | 9.6 | 0 |
Shareholding Trend
| Holder category | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 |
|---|---|---|---|---|---|---|
Promoters (%) | 57.40 | 62.37 | 63.26 | 65.30 | 65.88 | 65.88 |
Public (%) | 42.60 | 37.63 | 36.74 | 34.70 | 34.12 | 34.13 |
FII (%) | 0 | 0 | 0 | 0 | 0 | 0 |
DII incl. mutual funds (%) | 0 | 0 | 0 | 0 | 0 | 0 |
Number of shareholders | 7,702 | 9,668 | 11,298 | 9,972 | 9,446 | 8,512 |
Major Shareholders
| Holder | Stake (%) | As of | Source |
|---|---|---|---|
Archana Kandarp Amin (promoter) | 21.30 | Jun 2023 | Trendlyne |
Kandarp Krishnakant Amin (promoter) | 20.42 | Jun 2023 | Trendlyne |
Suchit Kandarp Amin (promoter group) | 8.68 | 19 Mar 2026 | ScanX (SAST disclosure) |
Archit Kandarp Amin (promoter) | 7.90 | Jun 2023 | Trendlyne |
Shimoli Archit Amin (promoter group) | 2.44 | Jun 2023 | Trendlyne |
Standard Greases & Specialities Pvt. Ltd. | 0.67 (pre-FY2022 dilution; current not disclosed) | Jun 2021 | Fuels & Lubes |
Competitive Landscape
Key Competitors
| # | Competitor | Country | Relevance to Archit | Scale indicator | Source |
|---|---|---|---|---|---|
| 1 | Anaven (Nouryon–Atul 50:50 JV) | India (Gujarat) | Direct domestic MCA competitor; India's largest MCA site | 32,000 tpa MCA, expandable to 60,000 tpa; production from 2020-21 | Nouryon/Anaven releases |
| 2 | Nouryon | Netherlands | Global MCA leader; plants in Netherlands, China, Japan | Global top producer | Nouryon release; GMI |
| 3 | Atul Ltd | India | JV partner in Anaven and captive MCA consumer (agro/pharma) | Fyers peer table: market cap ≈INR 18,016 Cr, annual PAT ≈INR 678 Cr (snapshot date not stated) | Fyers |
| 4 | CABB Group GmbH | Germany | World No. 2 MCA producer; JV in China with Jining Gold Power | Global top-2 | MarketsandMarkets; GMI |
| 5 | Denak Co. Ltd | Japan | MCA producer | — | Reports and Data |
| 6 | Daicel Corporation | Japan | MCA producer | — | Reports and Data |
| 7 | Niacet (now part of Kerry) | USA | MCA/derivatives | — | MarketsandMarkets |
| 8 | PCC Group | Poland | MCA producer | — | IMARC/ManufacturingPlantIndia |
| 9 | Chinese MCA/CAC exporters (multiple) | China | Price-setting import competition into India and export markets | Large aggregate capacity | Industry context (CABB/Jining JV) |
| 10 | Indian commodity-chemical micro-caps (e.g., Sanstar Chemicals, Stallion India referenced by MarketsMojo as valuation peers) | India | Equity-market peers, not product competitors | Micro-cap | MarketsMojo |
“—” = not publicly disclosed.
Peer Comparison FY2026
| Metric | Archit Organosys | Atul Ltd | Nouryon | CABB |
|---|---|---|---|---|
FY2026 / latest revenue | INR 1,410 M | — | Private (not publicly disclosed in reviewed sources) | Private |
Revenue growth | +12.2% (FY2026) | — | — | — |
EBITDA margin | 11.7% (FY2026) | — | — | — |
R&D intensity | Not disclosed (negligible) | — | — | — |
MCA capacity (India) | ~18,000 MTPA designed (6,000 Naroda + 12,000 Bhavnagar) before the 6,000 MTPA expansion; current total not disclosed | Via Anaven 32,000 tpa (50%) | Via Anaven | None in India |
“—” = not publicly disclosed.



